Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Active not recruiting 8Terminated 7Unknown 4Recruiting 4Withdrawn 1Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Colorectal Neoplasms 37Recurrence 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 28Lymphoma 26Pancreatic Neoplasms 25Melanoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Leukemia 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

necitumumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Respiratory Tract Diseases × Clear all
NCT02941601 2019-09-27

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Withdrawn
Thoracic

Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡